---
title: "Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294731166.md"
description: "Apnimed adopted second amended and restated bylaws effective Aug. 3, 2026, tied to its IPO. The changes introduce advance-notice rules for shareholder proposals, including director nominations, and update director nomination processes to align with the company’s new charter."
datetime: "2026-08-03T20:03:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294731166.md)
  - [en](https://longbridge.com/en/news/294731166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294731166.md)
generator: "portal-rs"
---

# Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposals

-   Apnimed adopted second amended and restated bylaws effective Aug. 3, 2026, tied to its initial public offering. \* The bylaws set new procedures for stockholder actions at meetings. \* They add advance-notice rules for stockholder proposals, including director nominations. \* The changes also update director nomination processes, aligning governance with the company’s new charter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-330509), on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APMD.US](https://longbridge.com/en/quote/APMD.US.md)

## Related News & Research

- [Morningside Venture Investments reports Apnimed common share acquisition valued at $5 million](https://longbridge.com/en/news/295009178.md)
- [Apnimed director Paul J. Sekhri acquires $200,000 in common shares](https://longbridge.com/en/news/294730912.md)
- [Cumberland Pharma says ifetroban Phase 2 DMD extension data not ready, pulls August 2026 timing](https://longbridge.com/en/news/297369585.md)
- [IBA publishes H1 2026 results presentation](https://longbridge.com/en/news/297180350.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**